Form 4: Neurogene Inc. CEO Rachel McMinn Reports Acquisition of Stock and Stock Options
SEC Form 4 Filing
Neurogene Inc. CEO Rachel McMinn reports the acquisition of 23,900 restricted stock units and 143,500 stock options.
Summary
- Rachel McMinn, CEO of Neurogene Inc., filed a Form 4 disclosing changes in beneficial ownership.
- On March 26, 2025, McMinn acquired 23,900 shares of common stock in the form of restricted stock units.
- These restricted stock units will vest in three equal annual installments starting on the first anniversary of the grant date, contingent on continued service to Neurogene.
- McMinn also acquired options to purchase 143,500 shares of Neurogene's common stock at an exercise price of $16.14.
- These options vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following three years, also subject to continued service.
- Following these transactions, McMinn beneficially owns 1,274,259 shares of common stock and 143,500 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option acquisitions by the CEO. While insider ownership can be a positive signal, this is a routine grant.
Positives
- The acquisition of stock and stock options by the CEO could be interpreted as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting schedules for the restricted stock units and stock options are contingent on the Reporting Person's continued provision of services to the Issuer.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in the CEO's holdings of Neurogene Inc. stock and stock options.
Stakeholder Impact
- The change in beneficial ownership may be of interest to shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/26/2025 | Date of the transaction: acquisition of restricted stock units and stock options. |
| 03/26/2025 | First vesting date for both restricted stock units and stock options. |
| 03/28/2025 | Date of signature for the Form 4 filing. |
Keywords
Neurogene Inc., Rachel McMinn, Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.